Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAD and MAD Study of LY3502970 in Healthy Subjects
NCT03929744Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2019
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of orforglipron in type 2 diabetes mellitus (T2DM) and obesity (17 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug at Day 42. Started Jun 2019; status: completed.
02
Drugs
orforglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT03929744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03929744.